Immatics Biotechnologies Gmbh
Clinical trials sponsored by Immatics Biotechnologies Gmbh, explained in plain language.
-
First patients test new 'T-Cell Engager' drug for Tough-to-Treat cancers
Disease control Recruiting nowThis is the first time a new drug called IMA401 is being tested in people. The main goal is to find a safe dose and see if it can help control advanced solid tumors that have come back or stopped responding to other treatments. The study will test IMA401 by itself and combined wi…
Phase: PHASE1 • Sponsor: Immatics Biotechnologies GmbH • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New 'Double-Target' drug enters human trials for Tough-to-Treat cancers
Disease control Recruiting nowThis trial is testing a new, first-of-its-kind drug called IMA402 in adults with advanced solid tumors that have come back or stopped responding to all standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. The study will enroll about 1…
Phase: PHASE1, PHASE2 • Sponsor: Immatics Biotechnologies GmbH • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC